REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 1, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 250,000 shares of the common stock of the Company to two newly hired employees with a per share exercise price of $9.16, the closing trading price on the grant date. One newly-hired Executive Vice President was granted options to purchase 150,000 shares and one newly-hired Senior Vice President was granted options to purchase 100,000 shares.
Read more at globenewswire.comProvided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.